U.S., July 19 -- ClinicalTrials.gov registry received information related to the study (NCT07072910) titled 'Cabergoline for Episodic Migraine' on May 19.
Brief Summary: The goal of this randomized, placebo-controlled, double-blind clinical trial is to evaluate the efficacy, safety, and tolerability of cabergoline for the prevention of episodic migraine in adults with 4-14 monthly migraine days (MMD). The main questions it aims to answer are:
1. Does once-weekly cabergoline (0.5 mg or 1.0 mg) reduce MMD compared to placebo?
2. What are the effects of cabergoline on headache severity, acute medication use, and patient-reported outcomes?
3. Is cabergoline safe to use in individuals with migraine?
Participants will:
Complete a 4-week bas...